Skip to main content
Clinical Trials/NCT05806372
NCT05806372
Not yet recruiting
Not Applicable

Biomarkers of Maternal Cardio-vascular Dysfunction in Pregnancies Complicated by Hypertensive Disorders of Pregnancy

IRCCS Burlo Garofolo1 site in 1 country128 target enrollmentOctober 15, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cardiovascular Diseases
Sponsor
IRCCS Burlo Garofolo
Enrollment
128
Locations
1
Primary Endpoint
Number of biomarkers predicting cardiomyocyte hypertrophy and fibroblast proliferation
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Profound and concomitant cardiovascular hemodynamic changes, necessary to support fetoplacental development and its increasing supply demands, occur during a physiological pregnancy characterized by an increase in cardiac output, heart rate and plasma volume, and fall in vascular resistance and blood pressure. The result of these changes is a volume overload that will lead to a compensatory transient left ventricular eccentric hypertrophy. This, together with the pro-inflammatory state typical of pregnancy, represents the pregnancy as a stress-test for the maternal cardiovascular system. Pregnancies complicated by hypertensive disorders of pregnancy (HDP), particularly those with early onset and/or complicated by intrauterine fetal growth restriction (FGR), are characterized by a cardiovascular maladaptation. Women who experienced HDP in pregnancy, especially pre-eclampsia (PE), more often develop later in life ischemic heart disease, hypertension and stroke, obesity, dyslipidemia, and end-stage renal disease.

Regardless its clinical impact, very little knowledge is available on the mechanisms by which PE could lead to cardiovascular disease (CVD), and, especially, to heart failure after pregnancy. Preliminary results suggest a cross-talk between pregnancy-induced biomarkers and cardio-vascular system. Particularly, cultures of neonatal rat cardiomyocytes and fibroblasts were used to investigate the role of the serum of women with HDP in regulating their proliferation. 5-ethynyl-2'-deoxyuridine (EdU) was administered to label DNA synthesis in proliferating cells. After 3 days of in vitro culture, EdU incorporation was analyzed upon immunofluorescence staining using specific antibodies by high content microscopy. A possible protective effect exerted by the selected sera against apoptosis was evaluated, as well, by Caspase activation. Moreover, the effect of cardiomyocytes and fibroblasts proliferation and apoptosis on maternal hemodynamic parameters was evaluated using median regression models. These data show that the serum of women with HDP triggers a net increase in the percentage of proliferating cardiomyocytes compared to controls. Moreover, there were relationship between cardiomyocytes and fibroblasts proliferation and maternal hemodynamics parameters thus, supporting the hypothesis that the serum of women with HDP may contain factors capable of stimulating cardiac cells in response to the cardiovascular stress-test

Registry
clinicaltrials.gov
Start Date
October 15, 2023
End Date
March 15, 2025
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
IRCCS Burlo Garofolo
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Pregnant women affected by HDP
  • Women ≥18 years old
  • Women able to give an informed consent
  • Uneventful pregnancy of women ≥18 years old
  • Women able to give an informed consent

Exclusion Criteria

  • No informed consent
  • Women \<18 years old
  • Presence of other maternal pathologies as viral disease, diabetes
  • Fetal chromosomal/structural anomalies

Outcomes

Primary Outcomes

Number of biomarkers predicting cardiomyocyte hypertrophy and fibroblast proliferation

Time Frame: 24 months post-partum

By exploiting the availability of a library of viral vectors encoding for the whole secretome (about 1200 secreted proteins) and the whole miRNAome (about 2000 human microRNAs) a high throughput screening will be carried out to identify molecules able to control the viability, proliferation and cell size of both primary cardiomyocytes and cardiac fibroblasts. Data mining methods for multi-target prediction, such as ensembles of predictive clustering trees, will be used to correlate multiple independent variables (e.g., potential biomarkers) to the multiple clinical outcomes (indices of cardio-vascular dysfunction measured by echocardiography).

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Vascular Changes in Pre-Eclamptic Patients and Its Impact on Pregnancy Outcome.Pre-Eclampsia
NCT03111576Beni-Suef University100
Active, not recruiting
Not Applicable
Maternal, uteroplacental and fetal haemodynamic effect of Nicardipine in severe pre-eclampsia. - CORCA IIHypertensive crisis in patients with severe pre-eclampsia needs to be treated to prevent maternal and fetal complications. The maternal, uteroplacental and fetal haemodynamic respose to antihypertensive treatment with Nicardipinehydrochloride will be evaluated in detail by materal echocardiography and fetal doppler ultrasound as well as by the effect on plasma Brain Natriuretic Peptide concentration (BNP) and parameters of the Renin- Angiotensin- Aldosterone system (RAAS).MedDRA version: 9.1Level: LLTClassification code 10040445Term: Severe pre-eclampsia, antepartumMedDRA version: 9.1Level: LLTClassification code 10053094Term: Doppler echocardiographyMedDRA version: 9.1Level: LLTClassification code 10045412Term: Ultrasound DopplerMedDRA version: 9.1Level: LLTClassification code 10058179Term: Hypertensive emergencyMedDRA version: 9.1Level: LLTClassification code 10038555Term: ReninMedDRA version: 9.1Level: LLTClassification code 10002491Term: Angiotensin IIMedDRA version: 9.1Level: LLTClassification code 10053406Term: Brain natriuretic peptideMedDRA version: 9.1Level: LLTClassification code 10001644Term: Aldosterone
EUCTR2007-000727-17-NLErasmus MC10
Completed
Not Applicable
Assessment of Cardiac Sparing in Fetal HypoxiaFetal Hypoxia
NCT03146507Assiut University210
Completed
Not Applicable
Cardiac Functions as a New Method for Evaluation of Fetal Anemia Pre and Post Intrauterine Fetal Blood TransfusionFetal Anemia as Antepartum Condition (Diagnosis)Rh Incompatible Blood Transfusion Nos
NCT03169907National Research Centre, Egypt150
Unknown
Not Applicable
Ultrasound Monitoring of Fetuses With Vascular Intra-uterine Growth Restriction (IUGR) Using the Isthmus Systolic Index (ISI): Feasibility, Comparison to Normal Fetuses and Association With Perinatal MortalityIUGR
NCT02813525University Hospital, Bordeaux320